Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brenner Tumor 1

Interventions

Paclitaxel 18Carboplatin 16Taxes 12Cisplatin 7Bevacizumab 7Immunoglobulin G 4Disulfides 4Topotecan 3VTX-2337 2SS1(dsFv)PE38 2Platinum 2Filgrastim 2Erlotinib Hydrochloride 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1paclitaxel poliglumex 1liposomal doxorubicin 1elesclomol 1belinostat 1Thiotepa 1Reverse Transcriptase Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Mental Status and Dementia Tests 1Melphalan 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Brenner Tumor × elesclomol × Clear all
NCT00888615 2021-10-20

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
58 enrolled 13 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡